Dunnya De‐Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dunnya De‐Silva has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Kwee L. Yong
University College London
3 shared publications - Ashutosh D. Wechalekar
National Amyloidosis Centre, University College London, London, United Kingdom
2 shared publications Claire Roddie
University College London Hospitals NHS Foundation Trust London UK
2 shared publications- Curly Morris
Belfast Trust Belfast UK
2 shared publications - Elizabeth H. Phillips
Division of Cancer Sciences, University of Manchester, Manchester, UK
2 shared publications - Gordon Cook
Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2 shared publications
Latest Publications
- Open Access
- 11 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , E33-E37
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- 11 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , E33-E37
Open AccessOutcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- Open Access
- 14 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (3) , E19-E22
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
- 14 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (3) , E19-E22
Open AccessUsing depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
- Open Access
- 13 January 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1243-1246
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...
- 13 January 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1243-1246
Open AccessIxazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...
- Open Access
- 10 January 2020
- Published by Wiley in European Journal of Haematology
- Vol. 104 (3) , 230-235
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
Objective: Cytomegalovirus (CMV) is an opportunistic herpesvirus, and reactivation of infection is possible in immunocompromised patients. Historically, the risk for haematology patients is restricted to those treated with an allogeneic transplant or T‐cell depleting agents. Bortezomib is a highly efficacious proteasome inhibitor widely used to treat multiple myeloma and light chain (AL) amyloidosis patients. The objective of this small prospective study was to quantify the risk of CMV reactivation associated with bortezomib treatment.Methods: Fifty‐seven consecutive multiple myeloma or AL amyloidosis patients commencing bortezomib‐based therapy were included. Viral copy numbers were established at baseline and then at fortnightly intervals during treatment. Pre‐emptive anti‐viral treatment was initiated in patients with a viral load >7500 copies/mL.Results: Reactivation of CMV was detected in 39% (n = 12/31) of seropositive bortezomib treated patients compared with 0% of CMV seronegative patients. Detectable DNAemia developed during the first two cycles of treatment in 83% (n = 10/12) patients. Anti‐viral treatment was initiated in 42% (n = 5/12), but no cases of active CMV disease were seen.Conclusion: This study suggests that there is a substantial risk of CMV reactivation in CMV‐seropositive plasma cell dyscrasia patients treated with bortezomib.
- 10 January 2020
- Published by Wiley in European Journal of Haematology
- Vol. 104 (3) , 230-235
Open AccessCytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
Objective: Cytomegalovirus (CMV) is an opportunistic herpesvirus, and reactivation of infection is possible in immunocompromised patients. Historically, the risk for haematology patients is restricted to those treated with an allogeneic transplant or T‐cell depleting agents. Bortezomib is a highly efficacious proteasome inhibitor widely used to treat multiple myeloma and light chain (AL) amyloidosis patients. The objective of this small prospective study was to quantify the risk of CMV reactivation associated with bortezomib treatment.Methods: Fifty‐seven consecutive multiple myeloma or AL amyloidosis patients commencing bortezomib‐based therapy were included. Viral copy numbers were established at baseline and then at fortnightly intervals during treatment. Pre‐emptive anti‐viral treatment was initiated in patients with a viral load >7500 copies/mL.Results: Reactivation of CMV was detected in 39% (n = 12/31) of seropositive bortezomib treated patients compared with 0% of CMV seronegative patients. Detectable DNAemia developed during the first two cycles of treatment in 83% (n = 10/12) patients. Anti‐viral treatment was initiated in 42% (n = 5/12), but no cases of active CMV disease were seen.Conclusion: This study suggests that there is a substantial risk of CMV reactivation in CMV‐seropositive plasma cell dyscrasia patients treated with bortezomib.